A single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in individuals with obesity without diabetes

被引：0

作者：

Thennati, R. ^{[1
]}

Burade, V. ^{[1
]}

Natarajan, M. ^{[1
]}

Shahi, P. ^{[1
]}

Nagaraja, R. ^{[1
]}

Panchal, S. ^{[1
]}

Agrawal, S. ^{[1
]}

Jandrain, B. ^{[2
,3
]}

Duvauchelle, T. ^{[4
]}

Garcia-Ocana, A. ^{[5
]}

Rutter, G. A. ^{[6
,7
]}

Pratley, R. E. ^{[8
]}

Thorens, B. ^{[9
]}

Vilsboll, T. ^{[10
]}

机构：

[1] Sun Pharmaceut Ind Ltd, High Impact Innovat Sustainable Hlth Solut HISH, Vadodara, Gujarat, India

[2] ATC Co, Clin Pharmacol Unit, Liege, Belgium

[3] Acad Hosp Leige, Div Diabet Nutr & Metab Disorders, Liege, Belgium

[4] Phaster1, Le Plessis Trevise, France

[5] Arthur Riggs Diabet & Metab Res Inst, Dept Mol & Cellular Endocrinol, Ruth B & Robert K Lanman Endowed Chair Gene Regul, Duarte, CA USA

[6] Univ Montreal, CR CHUM, Montreal, PQ, Canada

[7] Imperial Coll London, Div Diabet Endocrin & Metab, Sect Cell Biol & Funct Genom, Dept Metab Digest Reprod, London, England

[8] AdventHlth Translat Res Inst, Orlando, FL USA

[9] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland

[10] Univ Copenhagen, Clin Res, Steno Diabet Ctr Copenhagen, Copenhagen, Denmark

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

636

引用

页码：S320 / S321

页数：2